The diagnostic performance of T1 mapping in the assessment of breast lesions: A preliminary study

PURPOSE

To assess T1 mapping performance in distinguishing between benign and malignant breast lesions and to explore its correlation with histopathologic features in breast cancer.

METHODS

This study prospectively enrolled 103 participants with a total of 108 lesions, including 25 benign and 83 malignant lesions. T1 mapping, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) were performed. Two radiologists independently outlined the ROIs and analyzed T1 and apparent diffusion coefficient (ADC) values for each lesion, assessing interobserver reliability with the intraclass correlation coefficient (ICC). T1 and ADC values were compared between benign and malignant lesions, across different histopathological characteristics (histological grades, estrogen, progesterone and HER2 receptors expression, Ki67, N status). Receiver operating characteristic (ROC) analysis and Pearson correlation coefficient (ρ) were performed.

RESULTS

T1 values showed statistically significant differences between benign and malignant groups (P < 0.001), with higher values in the malignant (1817.08 ms ± 126.64) compared to the benign group (1429.31 ms ± 167.66). In addition, T1 values significantly increased in the ER (-) group (P = 0.001). No significant differences were found in T1 values among HER2, Ki67, N status, and histological grades groups. Furthermore, T1 values exhibited a significant correlation (ρ) with ER (P < 0.01) and PR (P = 0.03). The AUC for T1 value in distinguishing benign from malignant lesions was 0.69 (95 % CI: 0.55 - 0.82, P = 0.005), and for evaluating ER status, it was 0.75 (95 % CI: 0.62 - 0.87, P = 0.002).

CONCLUSIONS

T1 mapping holds the potential as an imaging biomarker to assist in the discrimination of benign and malignant breast lesions and assessing the ER expression status in breast cancer.

Assessing the influence of the menstrual cycle on APT CEST-MRI in the human breast

PURPOSE

In fibroglandular breast tissue, conventional dynamic contrast-enhanced MR-mammography is known to be affected by water content changes during the menstrual cycle. Likewise, amide proton transfer (APT) chemical exchange saturation transfer (CEST)-MRI might be inherently prone to the menstrual cycle, as CEST signals are indirectly detected via the water signal. The purpose of this study was to investigate the influence of the menstrual cycle on APT CEST-MRI in fibroglandular breast tissue.

METHOD

Ten healthy premenopausal women (19-34 years) were included in this IRB approved prospective study and examined twice during their menstrual cycle. Examination one and two were performed during the first half (day 2-8) and the second half (day 15-21) of the menstrual cycle, respectively. As a reference for the APT signal in malignant breast tumor tissue, previously reported data of nine breast cancer patients were included in this study. CEST-MRI (B₁ = 0.7μT) was performed on a 7 T whole-body scanner followed by a multi-Lorentzian fit analysis. The APT signal was corrected for B₀/B₁-field inhomogeneities, fat signal contribution, and relaxation effects of the water signal and evaluated in the fibroglandular breast tissue. Intra-individual APT signal differences between examination one and two were compared using the Wilcoxon signed-rank test. The level of significance was set at p < 0.05.

RESULTS

The APT signal showed no significant difference in the fibroglandular breast tissue of healthy premenopausal volunteers throughout the menstrual cycle (p = 1.00) (examination 1 vs. examination 2: mean and standard deviation = 3.24 ± 0.68%Hz vs. 3.30 ± 0.73%Hz, median and IQR = 3.36%Hz and 0.87%Hz vs. 3.38%Hz and 0.71%Hz).

CONCLUSION

The present study provides an important basis for the clinical application of APT CEST-MRI as an additional contrast mechanism in MR-mammography, as menstrual cycle-related APT signal fluctuations seem to be negligible compared to the APT signal increase in breast cancer tissue.

The influence of spatial resolution on the spectral quality and quantification accuracy of whole-brain MRSI at 1.5T, 3T, 7T, and 9.4T

PURPOSE

Inhomogeneities in the static magnetic field (B₀ ) deteriorate MRSI data quality by lowering the spectral resolution and SNR. MRSI with low spatial resolution is also prone to lipid bleeding. These problems are increasingly problematic at ultra-high fields. An approach to tackling these challenges independent of B₀ -shim hardware is to increase the spatial resolution. Therefore, we investigated the effect of improved spatial resolution on spectral quality and quantification at 4 field strengths.

METHODS

Whole-brain MRSI data was simulated for 3 spatial resolutions and 4 B₀ s based on experimentally acquired MRI data and simulated free induction decay signals of metabolites and lipids. To compare the spectral quality and quantification, we derived SNR normalized to the voxel size (nSNR), linewidth and metabolite concentration ratios, their Cramer-Rao-lower-bounds (CRLBs), and the absolute percentage error (APE) of estimated concentrations compared to the gold standard for the whole-brain and 8 brain regions.

RESULTS

At 7T, we found up to a 3.4-fold improved nSNR (in the frontal lobe) and a 2.8-fold reduced linewidth (in the temporal lobe) for 1 cm³ versus 0.25 cm³ resolution. This effect was much more pronounced at higher and less homogenous B₀ (1.6-fold improved nSNR and 1.8-fold improved linewidth in the parietal lobe at 3T). This had direct implications for quantification: the volume of reliably quantified spectra increased with resolution by 1.2-fold and 1.5-fold (when thresholded by CRLBs or APE, respectively).

CONCLUSION

MRSI data quality benefits from increased spatial resolution particularly at higher B₀ , and leads to more reliable metabolite quantification. In conjunction with the development of better B₀ shimming hardware, this will enable robust whole-brain MRSI at ultra-high field.

Repeatability and reproducibility of 3D MR fingerprinting relaxometry measurements in normal breast tissue

BACKGROUND

The 3D breast magnetic resonance fingerprinting (MRF) technique enables T₁ and T₂ mapping in breast tissues. Combined repeatability and reproducibility studies on breast T₁ and T₂ relaxometry are lacking.

PURPOSE

To assess test-retest and two-visit repeatability and interscanner reproducibility of the 3D breast MRF technique in a single-institution setting.

STUDY TYPE

Prospective.

SUBJECTS

Eighteen women (median age 29 years, range, 22-33 years) underwent Visit 1 scans on scanner 1. Ten of these women underwent test-retest scan repositioning after a 10-minute interval. Thirteen women had Visit 2 scans within 7-15 days in same menstrual cycle. The remaining five women had Visit 2 scans in the same menstrual phase in next menstrual cycle. Five women were also scanned on scanner 2 at both visits for interscanner reproducibility.

FIELD STRENGTH/SEQUENCE

Two 3T MR scanners with the 3D breast MRF technique.

ASSESSMENT

T₁ and T₂ MRF maps of both breasts.

STATISTICAL TESTS

Mean T₁ and T₂ values for normal fibroglandular tissues were quantified at all scans. For variability, between and within-subjects coefficients of variation (bCV and wCV, respectively) were assessed. Repeatability was assessed with Bland-Altman analysis and coefficient of repeatability (CR). Reproducibility was assessed with interscanner coefficient of variation (CoV) and Wilcoxon signed-rank test.

RESULTS

The bCV at test-retest scans was 9-12% for T₁ , 7-17% for T₂ , wCV was <4% for T₁ , and <7% for T₂ . For two visits in same menstrual cycle, bCV was 10-15% for T₁ , 13-17% for T₂ , wCV was <7% for T₁ and <5% for T₂ . For two visits in the same menstrual phase, bCV was 6-14% for T₁ , 15-18% for T₂ , wCV was <7% for T₁ , and <9% for T₂ . For test-retest scans, CR for T₁ and T₂ were 130 msec and 11 msec. For two visit scans, CR was <290 msec for T₁ and 10-14 msec for T₂ . Interscanner CoV was 3.3-3.6% for T₁ and 5.1-6.6% for T₂ , with no differences between interscanner measurements (P = 1.00 for T₁ , P = 0.344 for T₂ ).

DATA CONCLUSION

3D breast MRF measurements are repeatable across scan timings and scanners and may be useful in clinical applications in breast imaging.

LEVEL OF EVIDENCE

2 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2019;50:1133-1143.

Three-dimensional MR Fingerprinting for Quantitative Breast Imaging

Purpose To develop a fast three-dimensional method for simultaneous T1 and T2 quantification for breast imaging by using MR fingerprinting. Materials and Methods In this prospective study, variable flip angles and magnetization preparation modules were applied to acquire MR fingerprinting data for each partition of a three-dimensional data set. A fast postprocessing method was implemented by using singular value decomposition. The proposed technique was first validated in phantoms and then applied to 15 healthy female participants (mean age, 24.2 years ± 5.1 [standard deviation]; range, 18-35 years) and 14 female participants with breast cancer (mean age, 55.4 years ± 8.8; range, 39-66 years) between March 2016 and April 2018. The sensitivity of the method to B₁ field inhomogeneity was also evaluated by using the Bloch-Siegert method. Results Phantom results showed that accurate and volumetric T1 and T2 quantification was achieved by using the proposed technique. The acquisition time for three-dimensional quantitative maps with a spatial resolution of 1.6 × 1.6 × 3 mm³ was approximately 6 minutes. For healthy participants, averaged T1 and T2 relaxation times for fibroglandular tissues at 3.0 T were 1256 msec ± 171 and 46 msec ± 7, respectively. Compared with normal breast tissues, higher T2 relaxation time (68 msec ± 13) was observed in invasive ductal carcinoma (P < .001), whereas no statistical difference was found in T1 relaxation time (1183 msec ± 256; P = .37). Conclusion A method was developed for breast imaging by using the MR fingerprinting technique, which allows simultaneous and volumetric quantification of T1 and T2 relaxation times for breast tissues. © RSNA, 2018 Online supplemental material is available for this article.

Background parenchymal enhancement on breast MRI: influence of menstrual cycle and breast composition

PURPOSE

To evaluate the menstrual cycle and breast composition influence on background parenchymal enhancement of breast magnetic resonance imaging (MRI) and to investigate the optimal time for breast MR examinations.

MATERIALS AND METHODS

We evaluated the dynamic contrast-enhanced breast MR images of 238 women who had completed a questionnaire survey about menstrual status. On MRI, the degree of enhancement (DE) of normal parenchyma was measured in the images 2 minutes and 6 minutes after contrast injection. A comparison between premenopausal and postmenopausal women and a separate comparison between dense breasts and fatty breasts were analyzed according to the premenopausal women's menstrual cycle.

RESULTS

Premenopausal women showed significantly higher DE than the postmenopausal women (P<0.001). In premenopausal women, overall DE of fatty breasts and dense breasts was not different. However, fatty breasts showed the highest DE in the 4th week and lowest DE in the 2nd week, while dense breasts showed the highest DE in the 3rd week and the lowest DE in the 4th week of menstrual cycle.

CONCLUSION

The influence of menstrual cycle on the enhancement of breast parenchyma is different according to the breast composition. The optimal time for breast MRI could be different for dense and fatty breasts.

Normal breast parenchyma: contrast enhancement kinetics at dynamic MR mammography--influence of anthropometric measures and menopausal status

PURPOSE

To study T1 baseline signal intensity (SI) and contrast material enhancement kinetics of normal breast parenchyma by using dynamic contrast-enhanced (DCE) magnetic resonance (MR) mammography and to determine the influence of anthropometric measures and menopausal status on the variability of these features.

MATERIALS AND METHODS

Institutional review board approval and written informed consent were obtained. Between June 2008 and September 2011, 345 women (age range, 26-81 years; mean age, 51.3 years ± 11.6 [standard deviation]) underwent DCE MR mammography, with T1-weighted three-dimensional MR images (repetition time msec/echo time msec, 8.86/4.51; flip angle, 25°) acquired with a 1.5-T whole-body MR unit before and 1, 2, 3, 4, and 5 minutes after a gadobutrol bolus injection of 0.1 mmol per kilogram of body weight. Regions of interest were traced manually, and T1 SI of parenchyma was recorded. The influence of different predictors of T1 baseline SI and contrast enhancement was studied by using random-effects models.

RESULTS

T1 baseline SI varied considerably between women, with a mean of 167.7 ± 49.2 (71.4-424.7 [range]) and 175.9 ± 48.9 (51.8-458.3) in the right and the left breast, respectively (P < .01). T1 baseline SI increased linearly with age (P < .0001) and body weight (P < .0001). After contrast material delivery, relative percentage of enhancement was 8.1%, 13.8%, 18.2%, 22.1%, and 24.6% at 1, 2, 3, 4, and 5 minutes, respectively, but varied considerably between women. Contrast enhancement was 9.3% in the lowest quintile and 47.4% in the highest. Contrast enhancement increased with body weight (P < .01) but decreased in postmenopausal women (P < .01). Women with higher baseline T1 SI tended to have a higher contrast enhancement slope.

CONCLUSION

Anthropometric measures and menopausal status contribute to a large variability in contrast enhancement of normal breast parenchyma. This might influence the interpretation of contrast enhancement kinetics of breast lesions and current strategies for determining contrast medium dose for breast MR imaging.

Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy

OBJECTIVES

To investigate effects of menopausal status, oral contraceptives (OC), and postmenopausal hormone therapy (HT) on normal breast parenchymal contrast enhancement (CE) and non-mass-like enhancing areas in magnetic resonance mammography (MRM).

METHODS

A total of 459 female volunteers (mean age 49.1 ± 12.5 years) underwent T1-weighted 3D MRM 1-5 min after bolus injection of gadobutrol. Quantitative analysis was performed in normal breast parenchyma by manually tracing regions of interest and calculating percentage CE. Semiquantitative analysis was performed in non-mass-like enhancing areas, and signal intensity changes were characterised by five predefined kinetic curve types. The influence of OC (n = 69) and HT (n = 24) on CE was studied using random effects models.

RESULTS

Breast parenchymal enhancement was significantly higher in premenopausal than in postmenopausal women (P < 0.001). CE decreased significantly with the use of OC (P = 0.01), while HT had negligible effects (P = 0.52). Prevalence of kinetic curve types of non-mass-like enhancement differed strongly between pre- and postmenopausal women (P < 0.0001), but was similar in OC users and non-OC users (P = 0.61) as well as HT users and non-HT users (P = 0.77).

CONCLUSIONS

Normal breast parenchymal enhancement and non-mass-like enhancing areas were strongly affected by menopausal status, while they were not affected by HT use and only moderately by OC use.

KEY POINTS

Breast parenchymal enhancement at MR mammography is stronger in premenopausal than postmenopausal women. The prevalence of strong enhancing non-mass-like areas is greater before menopause. Such enhancing non-mass-like areas may impair lesion detection in premenopausal women. Breast parenchymal enhancement is only marginally affected by hormone use. Discontinuation of hormone use before MR mammography may be unnecessary.

Physiologic Changes in Breast Magnetic Resonance Imaging during the Menstrual Cycle: Perfusion Imaging, Signal Enhancement, and Influence of the T1 Relaxation Time of Breast Tissue

This study was undertaken to determine the best time during the menstrual cycle to perform dynamic breast magnetic resonance imaging (MRI). The contralateral "normal" breast of 50 premenopausal women (mean age 40.4 +/- 6.4 years, range 30--52 years) were enrolled in a protocol designed to correlate an ipsilateral suspicious breast lesion with pathology. The contralateral breast in each patient was examined with palpation and mammography prior to MRI on a 1.5 T scanner using gradient echo and dynamic contrast-enhanced echo-planar without and following gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) injection. Pre-contrast T1 relaxation times were measured before calculating extraction flow product (EFP) maps using a multicompartmental model. T1, EFP, and enhancement were measured in the control breast on four slices centered around the nipple and recorded as a function of the phases of the menstrual cycle. Lesions or areas with focal enhancement were excluded. Analysis of variance and Fisher's tests were performed. The cyclic changes in T1 relaxation time were not significant (p>0.2). EFP and enhancement varied significantly during the cycle (p<0.003 and p<0.004, respectively), with low values during the first half of the cycle and high values during the second half. The lowest values of EFP and enhancement (5.5+/-2.9 ml/100 g/min and 26+/-17%) were observed during the proliferative phase (days 3--7), and the highest values (17+/-10.2 ml/100 g/min and 104+/-28%) were observed during the secretory phase (days 21-27) (p<0.0006 and p<0.0008, respectively). Dynamic breast MRI should be performed during first half of the menstrual cycle (days 3--14) in order to minimize interpretative difficulties related to the uptake of gadolinium in normal breast tissue due to hormonal fluctuations during the menstrual cycle.

Menstrual cycle variation of apparent diffusion coefficients measured in the normal breast using MRI

Recent investigations have shown that tumors may be distinguished from benign lesions in the breast based on differences in apparent diffusion coefficient (ADC) values. The goal of this study was to assess the magnitude of normal variations in the measured ADC of breast parenchyma during the menstrual cycle. Eight healthy female subjects were scanned once a week for 4 weeks, using a diffusion-weighted single-shot fast spin-echo (DW-SSFSE) sequence. The ADC of breast fibroglandular tissue was calculated for each woman at each time point. Results showed a trend of decreased ADC during the second week of the cycle, and increased ADC during the final week. However, no significant influence of menstrual cycle on breast ADC values was identified. The results of this study show that the normal fluctuation of breast ADC is relatively small, and the coefficient of variation was determined to be 5.5% for our group of volunteers during a menstrual cycle. Nonetheless, breast diffusion measurements for tumor differentiation and evaluation of treatment response should be interpreted with consideration of normal variability.

Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study

PURPOSE

The purpose of this study was to investigate, using MRI, the potential morphologic effects of hormonal replacement therapy (HRT) on breast tissue in post-menopausal women.

METHOD

Five subjects were enrolled who were treated subsequently with both estrogen (2 mg/day) and a combination of estrogen (2 mg/day) and progestagen (1 mg/day). T1-weighted (TR 11 ms, TE 4.65 ms, flip angle 35 degrees, two excitations) 3D MR scans were acquired on a 1.5 T whole-body scanner before therapy and after each regimen. With use of a segmentation algorithm and histogram evaluation, parenchymal tissue/fat ratios were calculated over targeted volumes and changes were assessed.

RESULTS

An increase in these ratios was observed in two subjects after receiving the combined therapy, indicating a change in parenchymal pattern, whereas no obvious changes were detected in any of the subjects during the estrogen-based therapy.

CONCLUSION

MRI is able to detect and quantitate changes in breast parenchyma during HRT.